Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...
Lower eGFR and higher urinary protein-to-creatinine ratio were associated with greater risks for cognitive impairment across the chronic kidney disease spectrum, according to study data published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results